Lupin-Zentiva Ink $50M Biosimilar Deal

  Published 9 months ago

Lupin partners with Zentiva to develop and market biosimilars, securing $50M tied to regulatory milestones and profit-sharing.

  • Lupin will develop, manufacture, and supply biosimilars across agreed territories, retaining rights in USA and Canada.
  • Zentiva to commercialize across Europe and CIS, using its strong regulatory and marketing infrastructure.
  • The deal excludes any acquisition and involves no related-party interest or promoter involvement.

You might like these

Magellanic Cloud Q1 PBT Rises 6%

India's NABARD to Issue $2.3B Deep-Discount Bonds by 2027

MRPL Reports Q1 Loss, Revenue Drops

RBI Dovish Pause May Lower Bond Yields

Cipla Rises on Strong Q1 and U.S. Hopes

Lodha Q1 Profit Jumps 39% YoY

Bharti Hexacom Downgrade: Risks & Growth Outlook

News that matters the most ⚡